Modus Therapeutics Holding

Modus Therapeutics is a Swedish biotech company developing sevuparin for diseases with high unmet medical need. The Company’s near-term focus is to develop sevuparin for patients with sepsis/septic shock, a severe and often fatal condition.

Modus is backed by Karolinska Development (Nasdaq Stockholm: KDEV), KDev Investments AB, (part of Karolinska Development AB and Rosetta Capital), The Foundation for Baltic and European Studies (Östersjöstiftelsen) and Praktikerinvest AB. Different possibilities to finance Modus’ further development of Sevuparin in Sepsis/Septic shock are under active exploration.